---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| 5-HT | 5-hydroxytryptamine (serotonin) |
| 5-HT2A | 5-hydroxytryptamine 2A receptor |
| ACP | American College of Physicians |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| ASC | Altered States of Consciousness questionnaire |
| ATRQ | Antidepressant Treatment Response Questionnaire |
| AUC | Area under the concentration-time curve |
| BDI-II | Beck Depression Inventory, second edition |
| BMI | Body mass index |
| BP | Blood pressure |
| C-SSRS | Columbia-Suicide Severity Rating Scale |
| CANMAT | Canadian Network for Mood and Anxiety Treatments |
| CANTAB | Cambridge Neuropsychological Test Automated Battery |
| CBT | Cognitive behavioral therapy |
| CCAE | Commercial Claims and Encounters database |
| CCTV | Closed-circuit television |
| CFB | Change from baseline |
| CGI-I | Clinical Global Impression-Improvement |
| CGI-S | Clinical Global Impression-Severity |
| CI | Confidence interval |
| CMS | Centers for Medicare & Medicaid Services |
| CNPV | Commissioner's National Priority Voucher |
| CPSM | Compass Psychological Support Model |
| CPT | Current Procedural Terminology |
| CRP | C-reactive protein |
| DBS | Deep brain stimulation |
| DEA | Drug Enforcement Administration |
| DLPFC | Dorsolateral prefrontal cortex |
| DMN | Default mode network |
| DoD | Department of Defense |
| DSM-5 | Diagnostic and Statistical Manual of Mental Disorders, fifth edition |
| DTD | Difficult-to-treat depression |
| ECT | Electroconvulsive therapy |
| EMA | European Medicines Agency |
| EQ-5D | EuroQol 5-dimension questionnaire |
| EQ-VAS | EuroQol visual analogue scale |
| ESK | Esketamine |
| FDA | U.S. Food and Drug Administration |
| GAD-7 | Generalized Anxiety Disorder 7-item scale |
| HAM-D | Hamilton Depression Rating Scale |
| HCP | Healthcare professional |
| HDRS | Hamilton Depression Rating Scale |
| HEDIS | Healthcare Effectiveness Data and Information Set |
| HIAA | Hydroxyindoleacetic acid |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| HRU | Healthcare resource utilization |
| ICER | Institute for Clinical and Economic Review |
| IDS-SR-30 | Inventory of Depressive Symptomatology, Self-Report, 30-item |
| ILAP | Innovative Licensing and Access Pathway |
| IQR | Interquartile range |
| IRR | Incidence rate ratio |
| ITT | Intention-to-treat |
| IV | Intravenous |
| LSD | Lysergic acid diethylamide |
| LSMD | Least squares mean difference |
| MACE | Major adverse cardiovascular events |
| MADRS | Montgomery-Åsberg Depression Rating Scale |
| MAOI | Monoamine oxidase inhibitor |
| MCID | Minimal clinically important difference |
| MDD | Major depressive disorder |
| MDE | Major depressive episode |
| MDMA | 3,4-Methylenedioxymethamphetamine |
| MedDRA | Medical Dictionary for Regulatory Activities |
| MHRA | Medicines and Healthcare products Regulatory Agency |
| MINI | Mini International Neuropsychiatric Interview |
| MSM | Maudsley Staging Model |
| MTI | Maudsley Treatment Inventory |
| NDA | New Drug Application |
| NHS | National Health Service |
| NICE | National Institute for Health and Care Excellence |
| NMDA | N-methyl-D-aspartate |
| NNH | Number needed to harm |
| NNT | Number needed to treat |
| NSDUH | National Survey on Drug Use and Health |
| OR | Odds ratio |
| PET | Pictorial Empathy Test |
| PHQ-9 | Patient Health Questionnaire 9-item |
| PK | Pharmacokinetics |
| PPPY | Per patient per year |
| PTSD | Posttraumatic stress disorder |
| Q-LES-Q | Quality of Life Enjoyment and Satisfaction Questionnaire |
| QALY | Quality-adjusted life-year |
| QIDS-SR | Quick Inventory of Depressive Symptomatology, Self-Report |
| QTcF | QT interval corrected by Fridericia's formula |
| RCT | Randomized controlled trial |
| REMS | Risk Evaluation and Mitigation Strategy |
| RMET | Reading the Mind in the Eyes Test |
| RR | Relative risk |
| rTMS | Repetitive transcranial magnetic stimulation |
| SAE | Serious adverse event |
| SD | Standard deviation |
| SDS | Sheehan Disability Scale |
| SE | Standard error |
| SGA | Second-generation antipsychotic |
| SMD | Standardized mean difference |
| SNRI | Serotonin-norepinephrine reuptake inhibitor |
| SNT | Stanford Neuromodulation Therapy |
| SSR | Scale of Social Responsibility |
| SSRI | Selective serotonin reuptake inhibitor |
| SVO | Social Value Orientation |
| TAU | Treatment as usual |
| TCA | Tricyclic antidepressant |
| TEAE | Treatment-emergent adverse event |
| TEQ | Toronto Empathy Questionnaire |
| TESAE | Treatment-emergent serious adverse event |
| TMS | Transcranial magnetic stimulation |
| TRD | Treatment-resistant depression |
| UGT | Uridine 5'-diphospho-glucuronosyltransferase |
| VA | Department of Veterans Affairs |
| VNS | Vagus nerve stimulation |
| WAC | Wholesale acquisition cost |
| WPAI | Work Productivity and Activity Impairment questionnaire |
| WSAS | Work and Social Adjustment Scale |
| XR | Extended release |

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
